1. Petrov, D., Mansfield, C., Moussy, A. & Hermine, O. ALS clinical trials review: 20 years of failure: Are we any closer to registering
a new treatment?. Front. Aging Neurosci. 9, 68. https://doi.org/10.3389/fnagi.2017.00068 (2017).
2. Sawada, H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert. Opin. Pharmacother. 18,
735–738. https://doi.org/10.1080/14656566.2017.1319937 (2017).
3. Acsadi, G. et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum. Gene
Ther. 13, 1047–1059. https://doi.org/10.1089/104303402753812458 (2002).
4. Sun, W., Funakoshi, H. & Nakamura, T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic
mouse model of ALS. J. Neurosci. 22, 6537–6548 (2002).
5. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. & Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse
ALS model. Science 301, 839–842. https://doi.org/10.1126/science.1086137 (2003).
6. Reyes, N. A. et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model
of amyotrophic lateral sclerosis. J. Clin. Invest. 120, 3673–3679. https://doi.org/10.1172/JCI42986 (2010).
7. Gould, T. W. & Oppenheim, R. W. Motor neuron trophic factors: therapeutic use in ALS?. Brain Res. Rev. 67, 1–39. https://doi.
org/10.1016/j.brainresrev.2010.10.003 (2011).
8. Chen, K. S., Sakowski, S. A. & Feldman, E. L. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Ann. Neurol.
79, 342–353. https://doi.org/10.1002/ana.24584 (2016).
9. Goutman, S. A. et al. Long-term phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann. Clin. Transl. Neurol. 5,
730–740. https://doi.org/10.1002/acn3.567 (2018).
10. Abati, E., Bresolin, N., Comi, G. P. & Corti, S. Preconditioning and cellular engineering to increase the survival of transplanted
neural stem cells for motor neuron disease therapy. Mol. Neurobiol. 56, 3356–3367. https://doi.org/10.1007/s12035-018-1305-4
(2019).
11. Tang, B. L. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy: A perspective on cell
biological mechanisms. Rev. Neurosci. 28, 725–738. https://doi.org/10.1515/revneuro-2017-0018 (2017).
12. Kim, K. S. et al. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS
mouse model. Cell. Transplant. 23, 1585–1597. https://doi.org/10.3727/096368913X673450 (2014).
13. Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389–1392.
https://doi.org/10.1126/science.1123511 (2006).
14. Yamanaka, K. et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11,
251–253. https://doi.org/10.1038/nn2047 (2008).
15. Minghetti, L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18, 315–321. https://doi.org/10.1097/01.
wco.0000169752.54191.97 (2005).
16. Henkel, J. S. et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal
cord tissue. Ann. Neurol. 55, 221–235. https://doi.org/10.1002/ana.10805 (2004).
17. Henkel, J. S., Beers, D. R., Siklos, L. & Appel, S. H. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are
increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 31, 427–437. https://d
oi.o
rg/1 0.1 016/j.m
cn.2 005.1 0.0 16 (2006).
18. Corti, S. et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and
skeletal muscle tissues. Brain 127, 2518–2532. https://doi.org/10.1093/brain/awh273 (2004).
19. Terashima, T. et al. Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective
microglial migration. J. Neurosci. Res. 92, 856–869. https://doi.org/10.1002/jnr.23368 (2014).
20. Chen, W. et al. The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J.
Neurosci. 24, 1136–1148. https://doi.org/10.1523/JNEUROSCI.1586-03.2004 (2004).
21. Furness, D. N. et al. A quantitative assessment of glutamate uptake into hippocampal synaptic terminals and astrocytes: New
insights into a neuronal role for excitatory amino acid transporter 2 (EAAT2). Neuroscience 157, 80–94. https://doi.org/10.1016/j.
neuroscience.2008.08.043 (2008).
22. Petr, G. T. et al. Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy
while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J. Neurosci. 35, 5187–5201. https://doi.
org/10.1523/JNEUROSCI.4255-14.2015 (2015).
23. Estrada-Sanchez, A. M., Montiel, T., Segovia, J. & Massieu, L. Glutamate toxicity in the striatum of the R6/2 Huntington’s disease
transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol. Dis. 34, 78–86. https://
doi.org/10.1016/j.nbd.2008.12.017 (2009).
24. Jacob, C. P. et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J. Alzheimers
Dis. 11, 97–116. https://doi.org/10.3233/jad-2007-11113 (2007).
25. Chotibut, T. et al. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson’s disease model. Mov.
Disord. 32, 1547–1556. https://doi.org/10.1002/mds.27077 (2017).
26. Proper, E. A. et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe
epilepsy. Brain 125, 32–43. https://doi.org/10.1093/brain/awf001 (2002).
27. Peterson, A. R. & Binder, D. K. Post-translational regulation of GLT-1 in neurological diseases and its potential as an effective
therapeutic target. Front. Mol. Neurosci. 12, 164. https://doi.org/10.3389/fnmol.2019.00164 (2019).
28. McCauley, M. E. & Baloh, R. H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 137, 715–730. https://doi.org/10.
1007/s00401-018-1933-9 (2019).
29. Bond, L. et al. A Metadata analysis of oxidative stress etiology in preclinical amyotrophic lateral sclerosis: Benefits of antioxidant
therapy. Front. Neurosci. 12, 10. https://doi.org/10.3389/fnins.2018.00010 (2018).
30. Mejzini, R. et al. ALS genetics, mechanisms, and therapeutics: Where are we now?. Front. Neurosci. 13, 1310. https://doi.org/10.
3389/fnins.2019.01310 (2019).
31. Lunn, J. S., Sakowski, S. A. & Feldman, E. L. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: Recent advances
and prospects for the future. Stem Cells 32, 1099–1109. https://doi.org/10.1002/stem.1628 (2014).
32. Ciervo, Y., Ning, K., Jun, X., Shaw, P. J. & Mead, R. J. Advances, challenges and future directions for stem cell therapy in amyotrophic
lateral sclerosis. Mol. Neurodegener. 12, 85. https://doi.org/10.1186/s13024-017-0227-3 (2017).
33. Philips, T. & Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease.
Lancet Neurol. 10, 253–263. https://doi.org/10.1016/S1474-4422(11)70015-1 (2011).
34. Lee, J. et al. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Exp. Neurobiol. 25, 233–240.
https://doi.org/10.5607/en.2016.25.5.233 (2016).
35. Ilieva, H., Polymenidou, M. & Cleveland, D. W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond.
J. Cell Biol. 187, 761–772. https://doi.org/10.1083/jcb.200908164 (2009).
36. Luo, X. G. & Chen, S. D. The changing phenotype of microglia from homeostasis to disease. Transl. Neurodegener. 1, 9. https://doi.
org/10.1186/2047-9158-1-9 (2012).
Scientific Reports |
(2021) 11:12803 |
https://doi.org/10.1038/s41598-021-92285-x
15
Vol.:(0123456789)
www.nature.com/scientificreports/
37. Lynch, M. A. The multifaceted profile of activated microglia. Mol. Neurobiol. 40, 139–156. https://doi.org/10.1007/s12035-009-
8077-9 (2009).
38. Huleihel, L. et al. Macrophage phenotype in response to ECM bioscaffolds. Semin. Immunol. 29, 2–13. https://doi.org/10.1016/j.
smim.2017.04.004 (2017).
39. Grassivaro, F. et al. Convergence between microglia and peripheral macrophages phenotype during development and neuroinflammation. J. Neurosci. 40, 784–795. https://doi.org/10.1523/JNEUROSCI.1523-19.2019 (2020).
40. Ajami, B. et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and
neurodegeneration models. Nat. Neurosci. 21, 541–551. https://doi.org/10.1038/s41593-018-0100-x (2018).
41. Du, L. et al. Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol. Neurobiol. 54, 7567–7584.
https://doi.org/10.1007/s12035-016-0245-0 (2017).
42. Brites, D. & Vaz, A. R. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front. Cell Neurosci. 8, 117. https://
doi.org/10.3389/fncel.2014.00117 (2014).
43. Geloso, M. C. et al. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front. Aging Neurosci. 9, 242.
https://doi.org/10.3389/fnagi.2017.00242 (2017).
44. Song, C., Zhang, Y. & Dong, Y. Acute and subacute IL-1beta administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for neuroprotection and neurodegeneration. J. Neuroinflamm. 10, 59. https://doi.org/10.
1186/1742-2094-10-59 (2013).
45. Meissner, F., Molawi, K. & Zychlinsky, A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc.
Natl. Acad. Sci. USA 107, 13046–13050. https://doi.org/10.1073/pnas.1002396107 (2010).
46. Pepe, G. et al. Selective proliferative response of microglia to alternative polarization signals. J. Neuroinflamm. 14, 236. https://doi.
org/10.1186/s12974-017-1011-6 (2017).
47. Li, R., Zhao, K., Ruan, Q., Meng, C. & Yin, F. Bone marrow mesenchymal stem cell-derived exosomal microRNA-124-3p attenuates neurological damage in spinal cord ischemia-reperfusion injury by downregulating Ern1 and promoting M2 macrophage
polarization. Arthritis Res. Ther. 22, 75. https://doi.org/10.1186/s13075-020-2146-x (2020).
48. Rossi, C. et al. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic
lateral sclerosis. Cell Death Dis. 9, 250. https://doi.org/10.1038/s41419-018-0288-4 (2018).
49. Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance
of glutamate. Neuron 16, 675–686. https://doi.org/10.1016/s0896-6273(00)80086-0 (1996).
50. Kong, Q. et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J. Clin. Invest. 124,
1255–1267. https://doi.org/10.1172/JCI66163 (2014).
51. Shaw, P. J., Forrest, V., Ince, P. G., Richardson, J. P. & Wastell, H. J. CSF and plasma amino acid levels in motor neuron disease:
Elevation of CSF glutamate in a subset of patients. Neurodegeneration 4, 209–216. https://doi.org/10.1006/neur.1995.0026 (1995).
52. Moser, H. W. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy. Brain 120(Pt 8), 1485–1508. https://doi.org/
10.1093/brain/120.8.1485 (1997).
53. Eichler, F. et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 377, 1630–1638. https://
doi.org/10.1056/NEJMoa1700554 (2017).
54. Chiot, A. et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival.
Nat. Neurosci. 23, 1339–1351. https://doi.org/10.1038/s41593-020-00718-z (2020).
55. Appel, S. H. et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71,
1326–1334. https://doi.org/10.1212/01.wnl.0000327668.43541.22 (2008).
56. Ogawa, N. et al. Gene therapy for neuropathic pain by silencing of TNF-alpha expression with lentiviral vectors targeting the
dorsal root ganglion in mice. PLoS ONE 9, e92073. https://doi.org/10.1371/journal.pone.0092073 (2014).
57. Terashima, T. et al. Enhancing the therapeutic efficacy of bone marrow-derived mononuclear cells with growth factor-expressing
mesenchymal stem cells for ALS in mice. iScience 23, 101764. https://doi.org/10.1016/j.isci.2020.101764 (2020).
Acknowledgements
We thank the investigators at the Central Research Laboratory Shiga University of Medical Science for their
technical support. This study was supported by MEXT KAKENHI Grant JP18K07498 and research funding
from the Takeda Science Foundation. The drawings of vector components were created with PowerPoint 2019
(Microsoft, Redmond, WA) by N.O. and T.T.
Author contributions
N.O. conducted the experiments, analyzed the data, and wrote the manuscript. T.T. provided advice on the
experimental procedures, designed the study, and assisted with writing and revising the manuscript. H.K., Y.S.,
J.O., Y.N., and M.K. provided advice on the experimental design and techniques, expertise, and feedback. All
authors reviewed the final manuscript.
Competing interests The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/
10.1038/s41598-021-92285-x.
Correspondence and requests for materials should be addressed to T.T.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Scientific Reports |
Vol:.(1234567890)
(2021) 11:12803 |
https://doi.org/10.1038/s41598-021-92285-x
16
www.nature.com/scientificreports/
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2021
Scientific Reports |
(2021) 11:12803 |
https://doi.org/10.1038/s41598-021-92285-x
17
Vol.:(0123456789)
...
論文の公開元へ
